The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study
Crossref DOI link: https://doi.org/10.1038/s41598-022-18889-z
Published Online: 2022-08-26
Update policy: https://doi.org/10.1007/springer_crossmark_policy
You, Liangkun
Zheng, Xinnan
Deng, Danchen
Pan, Hongming
Han, Weidong
Text and Data Mining valid from 2022-08-26
Version of Record valid from 2022-08-26
Article History
Received: 21 May 2022
Accepted: 22 August 2022
First Online: 26 August 2022
Competing interests
: The authors declare no competing interests.